668 related articles for article (PubMed ID: 24606458)
1. Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Zhou ZR; Liu SX; Zhang TS; Xia J; Li B
Asian Pac J Cancer Prev; 2014; 15(3):1313-20. PubMed ID: 24606458
[TBL] [Abstract][Full Text] [Related]
2. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
[TBL] [Abstract][Full Text] [Related]
3. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
[TBL] [Abstract][Full Text] [Related]
5. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
[TBL] [Abstract][Full Text] [Related]
6. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
7. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.
Goodman OB; Flaig TW; Molina A; Mulders PF; Fizazi K; Suttmann H; Li J; Kheoh T; de Bono JS; Scher HI
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):34-9. PubMed ID: 24080993
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
[TBL] [Abstract][Full Text] [Related]
9. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
Fizazi K; Flaig TW; Stöckle M; Scher HI; de Bono JS; Rathkopf DE; Ryan CJ; Kheoh T; Li J; Todd MB; Griffin TW; Molina A; Ohlmann CH
Ann Oncol; 2016 Apr; 27(4):699-705. PubMed ID: 26609008
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS
Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS
Eur Urol; 2022 Jul; 82(1):22-30. PubMed ID: 35397952
[TBL] [Abstract][Full Text] [Related]
14. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial.
Roy S; Sun Y; Morgan SC; Wallis CJD; King K; Zhou YM; D'souza LA; Azem O; Cueto-Marquez AE; Camden NB; Spratt DE; Kishan AU; Saad F; Malone S
Eur Urol; 2023 Jun; 83(6):571-579. PubMed ID: 36894488
[TBL] [Abstract][Full Text] [Related]
15. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
Morris MJ; Molina A; Small EJ; de Bono JS; Logothetis CJ; Fizazi K; de Souza P; Kantoff PW; Higano CS; Li J; Kheoh T; Larson SM; Matheny SL; Naini V; Burzykowski T; Griffin TW; Scher HI; Ryan CJ
J Clin Oncol; 2015 Apr; 33(12):1356-63. PubMed ID: 25624432
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.
Lorente D; Llacer C; Lozano R; de Velasco G; Romero-Laorden N; Rodrigo M; Sánchez-Iglesias Á; di Capua C; Castro E; Ferrer C; Sánchez-Hernández A; Olmos D
Eur Urol; 2021 Nov; 80(5):641-649. PubMed ID: 34373138
[TBL] [Abstract][Full Text] [Related]
17. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
18. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
[TBL] [Abstract][Full Text] [Related]
19. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
20. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
